SevenBridge Financial Group LLC Has $7.17 Million Stock Position in Johnson & Johnson (NYSE:JNJ)

SevenBridge Financial Group LLC lifted its position in shares of Johnson & Johnson (NYSE:JNJ) by 1.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 46,218 shares of the company’s stock after purchasing an additional 727 shares during the quarter. Johnson & Johnson makes up about 1.3% of SevenBridge Financial Group LLC’s investment portfolio, making the stock its 15th largest position. SevenBridge Financial Group LLC’s holdings in Johnson & Johnson were worth $7,166,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the company. Larson Financial Group LLC grew its stake in shares of Johnson & Johnson by 24.2% in the 3rd quarter. Larson Financial Group LLC now owns 20,198 shares of the company’s stock valued at $3,273,000 after purchasing an additional 3,932 shares during the period. Managed Asset Portfolios LLC boosted its stake in Johnson & Johnson by 2.4% in the 3rd quarter. Managed Asset Portfolios LLC now owns 167,332 shares of the company’s stock valued at $27,118,000 after buying an additional 3,866 shares in the last quarter. Sompo Asset Management Co. Ltd. grew its position in Johnson & Johnson by 6.5% in the third quarter. Sompo Asset Management Co. Ltd. now owns 65,516 shares of the company’s stock valued at $10,618,000 after acquiring an additional 4,010 shares during the period. Wescott Financial Advisory Group LLC raised its stake in Johnson & Johnson by 22.4% during the third quarter. Wescott Financial Advisory Group LLC now owns 20,358 shares of the company’s stock worth $3,299,000 after acquiring an additional 3,721 shares in the last quarter. Finally, Lane & Associates LLC boosted its stake in shares of Johnson & Johnson by 8.8% in the 3rd quarter. Lane & Associates LLC now owns 4,627 shares of the company’s stock valued at $750,000 after purchasing an additional 376 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Johnson & Johnson

In related news, VP Robert J. Decker sold 5,635 shares of the company’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the sale, the vice president now owns 18,973 shares in the company, valued at $3,131,683.38. This represents a 22.90 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

JNJ has been the subject of a number of recent analyst reports. Guggenheim increased their target price on shares of Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 6th. Royal Bank of Canada lifted their target price on shares of Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a research note on Wednesday, October 16th. Wolfe Research started coverage on Johnson & Johnson in a research report on Friday, November 15th. They set an “outperform” rating and a $190.00 price target on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Finally, Wells Fargo & Company raised their target price on Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 16th. Seven analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $175.94.

Johnson & Johnson Price Performance

JNJ opened at $155.17 on Friday. The company has a fifty day moving average price of $160.21 and a two-hundred day moving average price of $156.26. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. The firm has a market capitalization of $373.59 billion, a PE ratio of 22.46, a P/E/G ratio of 2.76 and a beta of 0.53. Johnson & Johnson has a 52 week low of $143.13 and a 52 week high of $168.85.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The business had revenue of $22.47 billion during the quarter, compared to the consensus estimate of $22.17 billion. During the same quarter in the prior year, the company posted $2.66 earnings per share. The firm’s revenue was up 5.2% on a year-over-year basis. As a group, analysts anticipate that Johnson & Johnson will post 9.93 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be issued a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.20%. The ex-dividend date of this dividend is Tuesday, November 26th. Johnson & Johnson’s dividend payout ratio is currently 71.78%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.